Can a pill combo outpace chemotherapy for aggressive breast cancer?
NCT ID NCT06375707
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study tests whether a combination of ribociclib (a targeted pill) and hormone therapy can shrink tumors faster and more effectively than chemotherapy in women with a fast-growing type of advanced breast cancer (HR-positive, HER2-negative). Participants receive ribociclib plus an endocrine therapy, with ovarian suppression if needed, and their outcomes are compared to those of similar patients who previously received chemotherapy. The main goal is to see how many patients experience tumor shrinkage, with additional measures including time to progression, survival, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ribociclib combined with endocrine therapy (anastrozole, letrozole, exemestane, or fulvestrant), with ovarian function suppression (goserelin) when indicated
- What this could lead to
- If effective, this combination could offer a targeted, less toxic alternative to chemotherapy for women with rapidly progressing HR+/HER2- advanced breast cancer, potentially improving response rates and quality of life.
- What could go wrong
- This is a phase II trial with a relatively small number of participants and no randomization, so results may not be definitive. Ribociclib can cause side effects like low blood cell counts and liver issues, and the comparison to historical chemotherapy data may introduce bias.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Real-world data may reveal true value of abemaciclib for advanced breast cancer
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- New drug sequence aims to outsmart advanced breast cancer
- Could a pill replace an IV for advanced breast cancer treatment?